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ABSTRACT 20	
 21	
Conjugation of proteins to drug-loaded polymeric structures is an attractive strategy for facilitating 22	
target-specific drug delivery for a variety of clinical needs. Polymers currently available for 23	
conjugation to proteins generally have limited chemical versatility for subsequent drug loading.  24	
Many polymers that do have chemical functionality useful for drug loading are often insoluble in 25	
water, making it difficult to synthesize functional protein-polymer conjugates for targeted drug 26	
delivery. In this work, we demonstrate that reactive, azlactone-functionalized polymers can be 27	
grafted to proteins, conjugated to a small molecule fluorophore, and subsequently internalized into 28	
cells in a receptor-specific manner. Poly(2-vinyl-4,4-dimethylazlactone) (PVDMA) synthesized 29	
using reversible addition-fragmentation transfer (RAFT) was modified post-polymerization with 30	
	 2	
substoichiometric equivalents of triethylene glycol monomethyl ether (mTEG) to yield reactive 31	
water-soluble, azlactone-functionalized copolymers. These reactive polymers were then 32	
conjugated to proteins holo-transferrin and ovotransferrin. Protein gel analysis verified successful 33	
conjugation of proteins to polymer, and protein-polymer conjugates were subsequently purified 34	
from unreacted proteins and polymers using size exclusion chromatography. Internalization 35	
experiments using a breast cancer cell line that overexpresses the transferrin receptor on its surface 36	
showed that the holo-transferrin-polymer conjugate was successfully internalized by cells in a 37	
mechanism consistent with receptor-mediated endocytosis. Our approach to protein-polymer 38	
conjugate synthesis offers a simple, tailorable strategy for preparing bioconjugates of interest for 39	
a broad range of biomedical applications.  40	
 41	
INTRODUCTION 42	
 43	
Treatment of numerous diseases could benefit from improved options for targeted delivery of 44	
drugs to disease-specific locations.  Two important challenges in medicine for which targeted 45	
delivery could significantly improve patient outcomes are delivery of therapeutics to the central 46	
nervous system and delivery of chemotherapeutics selectively to tumor cells.  The blood-brain 47	
barrier (BBB) frequently prevents therapeutics from sufficiently accessing brain tissue, creating a 48	
major bottleneck for developing treatments for diseases like Alzheimer’s disease and brain 49	
tumors.1,2  Often, drug development efforts for neurological diseases must focus on small molecule 50	
candidates constrained by a set of physicochemical properties that can facilitate their passage 51	
across the BBB.3  Receptor-mediated transcytosis (RMT) is a promising approach being developed 52	
to use native transport pathways to shuttle larger therapeutic complexes across the BBB.4,5  Initial 53	
reports of the ongoing clinical trials for the first RMT-based therapeutic to be used in humans have 54	
been positive,6 encouraging continued development of therapeutics using RMT pathways for drug 55	
delivery.  56	
Specific targeting of chemotherapeutic agents to tumor cells could significantly reduce 57	
toxic side effects that are currently caused by the systemic distribution of administered cytotoxic 58	
drugs in the body.7  In recent years, substantial progress has been made toward the general goal of 59	
targeted therapy using both passive and active targeting approaches.7  For example, antibody-drug 60	
conjugates have been developed that rely on the specific targeting of tumor biomarkers using 61	
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antibodies to deliver a toxic payload to tumor cells.8–10  There are, however, challenges with finding 62	
appropriate chemistries for conjugating the drug to the antibody, with continued need for improved 63	
linkers between antibodies and their drug payload that do not inhibit antibody targeting and that 64	
can release drug when the conjugate has reached the desired location.8  Inorganic and polymeric 65	
nanocarriers have also been explored for both passive and active targeting.11,12  Although several 66	
nanocarriers that passively target tumor cells have been approved for clinical use, no actively 67	
targeted nanocarriers have advanced past clinical trials to date.12  There remains a need for better 68	
drug carriers that actively target pathological cells.  69	
 Active targeting of drug carriers to particular cell types is generally achieved by 70	
conjugating a drug carrier to a ligand that binds specific cell-surface receptors.  Drug carriers 71	
include polymers and nanoparticles, and ligands can be proteins, peptides, or certain small 72	
molecules.7,11,12  Proteins are particularly useful as targeting ligands because they exhibit precise 73	
binding interactions with molecular partners.  Protein engineering permits the manipulation of 74	
these binding interactions such that a given targeting protein can be engineered to meet identified 75	
design parameters, such as a desired affinity or binding epitope on the receptor.13,14 Consequently, 76	
proteins, including antibodies and other protein classes, have found wide success on their own as 77	
therapeutics for a variety of diseases.15,16 To be useful as a targeting ligand for drug delivery 78	
applications, proteins that interact with a chosen disease marker need to be chemically coupled to 79	
the drug to be delivered. Versatile and straightforward chemistries to conjugate drugs to proteins 80	
are still needed.8  Polymers that link targeting proteins to drug molecules are a promising avenue 81	
for developing a modular strategy for synthesizing targeted drug delivery molecules, where any 82	
targeting protein of interest could be readily coupled to a drug molecule linked by a polymer that 83	
couples to protein and to drug.  Here, we report the development of protein-polymer conjugates 84	
for targeted drug delivery applications.  85	
Protein-polymer conjugates are being used in a variety of applications in medicine and 86	
industry.17–19 The first generation of protein-polymer conjugates were comprised of polyethylene 87	
glycol (PEG) attached to therapeutic proteins to extend the circulation time and reduce the 88	
immunogenicity of the therapeutics. Over the past several decades, more than a dozen PEGylated 89	
molecules have been approved for use in humans.20–22 While PEG continues to be the leading 90	
polymer for preparing clinically-relevant protein-polymer conjugates, PEG does have limitations, 91	
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such as non-degradability and potential immunogenicity,23 that necessitate the development of 92	
protein-polymer conjugates with an expanded selection of finely tuned functionalities.  93	
Numerous advances in the development of protein-polymer conjugates with expanded 94	
chemistries useful for biomedical applications have been reported in recent years.17–19,24,25 Strategies 95	
for controlled polymerization19,24–26 and site-specific conjugation24,25,27–34 of polymers to proteins have 96	
facilitated the synthesis of more well-defined protein-polymer conjugates. Site-specificity and 97	
control of polymer synthesis are jointly achieved with approaches that grow polymers from 98	
proteins functionalized with an initiator at a unique location in the protein sequence.24,31,33 While 99	
growing polymers from appropriately-functionalized proteins, termed ‘grafting-from,’ affords 100	
more easily purified conjugates,19,25,26 the grafting-from approach does limit to some extent the 101	
chemistries that can be incorporated into the polymer structure. In addition, grafting-from requires 102	
a new polymer to be synthesized each time the bioconjugate is prepared, which may lead to small 103	
variations in the polymer structure, even when controlled methods are used. In a ‘grafting-to’ 104	
approach, preformed polymers bearing end-group or side-chain reactive functionality are 105	
conjugated to proteins.25,35,36 A number of different chemistries have been used to facilitate grafting 106	
of polymers to proteins, including polymers bearing amine-reactive functionality such as NHS-107	
esters or anhydrides,25,36,37 maleimide or dibromomaleimide functionality for reaction with cysteine 108	
residues,25,36,38–40 and biorthogonal “click” reactions.25,34,36,41 Grafting-to permits incorporation of both 109	
water-soluble and water-insoluble functionalities into the polymer structure. For example, 110	
hydrophobic drugs are an important class of water-insoluble molecules that can be incorporated 111	
into polymer structures when using the grafting-to approach. Grafting-to also allows conjugation 112	
of a defined polymer structure to a variety of different proteins.  113	
In the work reported here, we explored the use of side-chain reactive polymers for the 114	
preparation of protein-polymer conjugates via a grafting-to approach. Side-chain reactive 115	
polymers and their subsequent post-polymerization modification42–45 offer opportunities for 116	
combinatorial synthesis of a broad range of polymer structures such that the influence of polymer 117	
structure on bioconjugate properties can be easily explored.46 Furthermore, these reactive groups 118	
could be used to tether drug molecules to the scaffold before protein conjugation. In particular, 119	
hydrophobic drugs can be more readily coupled to a polymer in organic solvent compared to 120	
directly coupling a hydrophobic drug to a protein in aqueous solution. From a drug delivery 121	
perspective, a polymer with a tunable number of sites for drug attachment is desirable because it 122	
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permits intentional selection of the number of drug molecules per protein-polymer conjugate. Such 123	
flexibility in drug loading enables targeting an appropriate concentration in the body within a 124	
particular drug’s therapeutic window. It is then possible to achieve a sufficiently high 125	
concentration of the drug at the disease site to have a desired therapeutic effect while remaining 126	
below concentrations in the body that cause unacceptable toxicities. The ability to conjugate a 127	
variety of active drug molecules directly to protein residues is more difficult than approaches that 128	
use a delivery scaffold.   129	
 We used the reactive polymer poly(2-vinyl-4,4-dimethylazlactone) (PVDMA, Figure 1) 130	
to prepare a series of protein-polymer conjugates. PVDMA is attractive for the preparation of 131	
bioconjugates for several reasons. It can be synthesized from the vinyl monomer using a variety 132	
of polymerization methods.43,45,47 In this current work, we synthesized PVDMA using reversible 133	
addition-fragmentation chain transfer (RAFT) polymerization, which has been demonstrated 134	
previously to yield well-defined azlactone-functionalized polymers (Figure 1A).47–50  Importantly 135	
for this work, the five-membered lactone of PVDMA rapidly undergoes ring-opening reactions 136	
with nucleophiles, such as amines and alcohols, including those found in native proteins.45,51 Thus, 137	
a broad range of polymeric structures and bioconjugates can be readily synthesized starting from 138	
the same template polymer. While azlactone-functionalized polymers have been used to 139	
immobilize proteins on a variety of solid supports or thin films,45,51 only a few examples of soluble 140	
protein-polymer conjugates have been reported.48,52,53 For example, Fontaine and coworkers 141	
demonstrated the feasibility of using the azlactone functional group for conjugation of  polymers 142	
to lysozyme48,52 while Weeks et al. reported the conjugation of recombinant elastin-like polypeptides 143	
to PVDMA.53 However, because PVDMA is not inherently water-soluble, these previous reports 144	
used organic solvents to conjugate the protein to the polymer.48,52,53   145	
In this work, we demonstrate the feasibility of synthesizing water-soluble, azlactone-146	
functionalized polymers and conjugating these reactive polymers to disease-relevant proteins. 147	
Stover and coworkers reported the synthesis of water-soluble azlactone-functionalized polymers 148	
through copolymerization of the azlactone monomer VDMA with a series of water-soluble 149	
comonomers.54 Others have demonstrated that PVDMA can be rendered water soluble by 150	
exhaustive functionalization with appropriate side chain functionality.55 In this report, we 151	
functionalized PVDMA with substoichiometric amounts of triethylene glycol monomethyl ether 152	
(abbreviated mTEG) to prepare reactive, water-soluble polymers (PVDMA-mTEG, Figure 1A). 153	
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This polymer readily conjugates to the proteins holo-transferrin (hTF) and ovotransferrin (OTF) 154	
in aqueous solution (Figure 1B). hTF represents a useful model protein for the development of 155	
targeted drug delivery scaffolds because the protein binds to and is internalized by cell-surface 156	
transferrin receptors (TFR) present on endothelial cells that comprise the blood brain barrier and 157	
expressed at high levels on many tumor cells.56  hTF has also been used recently in the synthesis of 158	
protein-polymer conjugates and shown to facilitate receptor-specific targeting of conjugates to 159	
cells expressing the transferrin receptor.57 Using confocal microscopy assays, we show that hTF-160	
PVDMA-mTEG conjugates are internalized specifically into a tumor cell line that expresses TFR. 161	
This work exemplifies a modular approach for synthesizing protein-polymer conjugates and offers 162	
a new system that can be easily tailored for targeted drug delivery to a variety of disease-specific 163	
cell types. 164	
 165	
 166	
 167	
Figure 1. Synthesis of protein-polymer conjugates via a modular grafting-to approach using water-soluble, 168	
azlactone-functionalized polymers. (A) PVDMA was synthesized by RAFT polymerization and functionalized with 169	
a substoichiometric equivalent of mTEG (0.3 molar eq. relative to repeat unit) to make the polymer soluble in water 170	
(PVDMA-mTEG). (B) PVDMA-mTEG can be subsequently grafted to a protein, including holo-transferrin shown 171	
here (PDB 3V83).  172	
 173	
RESULTS AND DISCUSSION 174	
 175	
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Synthesis and Characterization of mTEG-functionalized PVDMA. PVDMA was synthesized 176	
using RAFT polymerization58 (Figure 1A, step 1) to yield a well-defined homopolymer with Mn = 177	
13.1 kg/mol (Table 1). Water-soluble azlactone-functionalized polymers for protein conjugation 178	
were synthesized by treating the homopolymer with 0.3 equivalents of mTEG relative to the 179	
azlactone repeat unit (Figure 1A, step 2). DBU was used as a base catalyst and all reactions were 180	
stirred at 40 °C overnight. Figure 2A shows FT-IR spectra of PVDMA homopolymer and PVDMA 181	
treated with mTEG. The IR spectrum of PVDMA prior to functionalization (Figure 2A, black 182	
dashed curve) reveals peaks characteristic of the carbonyl (1820 cm-1) and imine (1670 cm-1) bonds 183	
of the azlactone ring. Treatment of PVDMA with 0.3 equivalents of mTEG (red curve) leads to a 184	
decrease in the carbonyl and imine peaks and the appearance of peaks at 1735 cm-1 (ester), 1650 185	
cm-1 (amide I), and 1540 cm-1 (amide II) that result from ring-opening of the lactone with an alcohol 186	
nucleophile. Quantitative analysis of mTEG functionalization using NMR spectroscopy revealed 187	
that mTEG was incorporated into the polymer in nearly quantitative yield (Table 1). GPC analysis 188	
of PVDMA functionalized with mTEG revealed an increase in molecular weight consistent with 189	
functionalization of the polymer (Table 1). GPC analysis also confirmed that no polymer 190	
crosslinking occurred during treatment with mTEG, based on observing no increase in dispersity 191	
comparing polymer before and after mTEG functionalization. The absence of crosslinking is 192	
expected since mTEG only has one nucleophile that is reactive with the azlactone group. Finally, 193	
while PVDMA can be functionalized with larger amounts of mTEG, polymers modified with 0.3 194	
equivalents proved to be soluble in water. Thus, this polymer, referred to hereafter simply as 195	
PVDMA-mTEG, was used for all experiments described here to provide the greatest number of 196	
remaining reactive groups in the polymer for additional modifications and protein conjugation.  197	
 198	
Table 1. Characterization of polymers by NMR spectroscopy and GPC. 199	
 200	
aMolar equivalents of mTEG relative to the azlactone repeat unit in the reaction.  bMolar equivalents of mTEG 201	
incorporated into the polymer was determined using 1H NMR spectroscopy. 4-Iodoanisole was added as an internal 202	
standard and mTEG functionalization was determined by comparing the integration of the ester peak at 4.22 ppm to 203	
the integration of the peak at 6.67 ppm arising from 4-iodoanisole. cNumber average molecular weight and dispersity 204	
determined by GPC in THF measured against polystyrene standards.  205	
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 206	
One potential challenge associated with using the azlactone moiety for protein conjugation 207	
in aqueous solution is that these groups are susceptible to hydrolysis. However, hydrolysis 208	
reactions are typically slower than reactions of azlactones with amines. Furthermore, azlactone 209	
groups have been shown to persist for several hours in water when copolymerized with certain 210	
water soluble monomers.54 To qualitatively characterize the rate of hydrolysis of PVDMA-mTEG, 211	
we acquired IR spectra of a polymer dissolved in water (Figure 2B) over time. The series of spectra 212	
shown in Figure 2B reveal that the lactone carbonyl peak (1820 cm-1) persists for at least 12 hours. 213	
The polymer fully hydrolyzes in 24 hours as evidenced by the complete disappearance of the 214	
lactone carbonyl peak at 1820 cm-1 (Figure 2B). Based on these data, we hypothesized that, 215	
following functionalization with mTEG, sufficient azlactones would remain on the polymer to 216	
permit reaction with amines on a protein (i.e., the N-terminus or lysine residues), but that all 217	
residual azlactone groups would fully hydrolyze during or after protein conjugation. This latter 218	
hydrolysis reaction is desirable in order to avoid unwanted reactions of the polymer with proteins 219	
on cells in subsequent cell internalization experiments.  220	
 221	
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 222	
Figure 2. Water-soluble, azlactone-functionalized copolymers can be synthesized by post-polymerization 223	
modification of PVDMA. (A) FT-IR spectra of PVDMA (black dashed curve) and PVDMA modified with 0.3 molar 224	
equivalents (Eq.) of mTEG relative to the repeat unit (red curve). The peaks at 1820 cm-1 (carbonyl) and 1670 cm-1 225	
(imine) are characteristic of the azlactone ring. Ring opening of the lactone with an alcohol nucleophile results in the 226	
disappearance of the azlactone peaks and the appearance of ester (1720 cm-1), amide I (1650 cm-1), and amide II (1540 227	
cm-1) peaks. (B) FT-IR spectra as a function of time of PVDMA-mTEG incubated in water.  FT-IR spectra revealed 228	
the disappearance of the azlactone carbonyl (1820 cm-1) peak and an increase in the peaks at 1735 cm-1 (ester+carboxylic 229	
acid carbonyl), 1650 cm-1 (amide I), and 1540 cm-1 (amide II). The strong peak at 1710 cm-1 corresponds to acetone, 230	
which was used to cast the polymer film on the ATR crystal. The legend refers to time in hours following dissolution 231	
of PVDMA-mTEG in water. 232	
 233	
Protein Holo-transferrin Conjugates to PVDMA-mTEG.  For our initial experiments, holo-234	
transferrin (hTF) was selected to determine the feasibility of conjugating proteins to PVDMA-235	
mTEG. hTF is an 80 kDa glycoprotein containing 58 lysine residues (UniProt P02787) and is the 236	
native protein ligand for the transferrin receptor (TFR).56 Upon binding its receptor, hTF gets 237	
internalized into cells through receptor-mediated endocytosis. The hTF-TFR interaction is of 238	
interest for a variety of clinical applications.56 For example, receptor-mediated transcytosis 239	
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facilitated by TFR has been studied for drug delivery across the blood-brain barrier to the central 240	
nervous system.59 TFR is also overexpressed in many cancers, which makes it an interesting 241	
receptor system to be used as a model for targeted drug delivery to tumor cells.60 Because PVDMA 242	
reacts readily with the primary amines in the N-termini and lysine residues in proteins,45,51 hTF 243	
provides ample reactive sites for conjugation.  244	
Conjugates were prepared by incubating PVDMA-mTEG with hTF in phosphate buffered 245	
saline (PBS) containing 15% v/v DMSO at 4 °C. Low concentrations of DMSO are commonly 246	
used to facilitate conjugation of reactive small molecules and polymers to proteins.37,61 We examined 247	
a range of molar ratios of polymer:protein for hTF conjugation reactions.  Successful conjugation 248	
of polymer to protein was assessed using SDS-PAGE (Figure 3). Lane 1 contains pure hTF protein 249	
with no polymer. Lane 2 contains PVDMA-mTEG polymer with no protein, which is not detected 250	
by the protein gel stain. Lanes 3 through 6 include conjugation reactions in which the amount of 251	
protein was kept constant while the amount of PVDMA-mTEG was increased.   Lane 3 reveals 252	
the presence of a faint band at higher molecular weight than the hTF protein band.  The apparent 253	
molecular weight of this band is consistent with the molecular weight of one protein and one 254	
polymer molecule, suggesting the formation of conjugates at a 1:1 molar ratio of protein:polymer. 255	
With higher amounts of polymer in the conjugation reaction (Figure 3, lane 4-6), we observe a 256	
band at a molecular weight consistent with a protein:polymer molar ratio of 1:2. Increasing the 257	
molar amount of polymer relative to protein resulted in a darkening of this higher molecular weight 258	
band.  We do not observe any protein bands at a molecular weight that suggests two or more 259	
proteins in a conjugate molecule with at least one polymer.  While all reactions show residual 260	
unreacted protein, as demonstrated by the presence of the original protein band in lanes 3-6, the 261	
intensities of these bands are increasingly reduced compared to the intensity of the protein only 262	
sample shown in lane 1. The same amount of total protein was loaded into lanes 1 and 3-6, and, 263	
therefore, reduction in the original protein band intensity further suggests successful protein-264	
polymer conjugation. Taken together, these data demonstrate that hTF conjugates to PVDMA-265	
mTEG through reactive, azlactone functionality in aqueous solution. 266	
 267	
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 268	
 269	
Figure 3. Protein hTF conjugates to PVDMA-mTEG.  Holo-transferrin (hTF) conjugates to PVDMA-mTEG in 270	
aqueous solution. The appearance of higher molecular weight bands and decrease in intensity of primary protein band 271	
indicate protein conjugation to polymer. Protein amounts in each lane were held constant. Lane 1 contains protein 272	
only, lane 2 contains PVDMA-mTEG only.  Lanes 3-6 contain unpurified protein-polymer conjugation reactions at 273	
an increasing amount of polymer relative to protein, keeping amount of protein constant. Molar ratios of protein to 274	
polymer molecules in reactions are: lane 3 = 1:5; lane 4 = 1:10; lane 5 = 1:20; lane 6 = 1:50. Samples are not reduced. 275	
Apparent molecular weights of the two protein-polymer conjugate bands are most consistent with protein:polymer 276	
conjugate ratios of 1:1 and 1:2.   277	
 278	
Protein-Polymer Conjugates can be Purified by Size Exclusion Chromatography.  Prior to use 279	
in receptor targeting experiments with a human cell line, protein-polymer conjugates were purified 280	
from unreacted protein and unreacted polymer. Samples were first concentrated and purified from 281	
low molecular weight species by using a centrifugal filtration device with a 10 kDa molecular 282	
weight cut-off (MWCO) before being loaded onto a size exclusion chromatography (SEC) column.  283	
Samples were analyzed by detecting absorbance at 220 nm.  Pure hTF protein exhibits a single 284	
narrow peak on SEC (Figure 4A, red solid curve).  PVDMA-mTEG exhibits a broad high 285	
molecular weight peak and a narrow low molecular weight peak (Figure S1A).  Unpurified protein-286	
polymer conjugates eluted at shorter retention times (i.e., higher molecular weight) relative to hTF 287	
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only and included low molecular weight species similar to polymer only samples (Figure 4A, black 288	
dashed curve). We were able to collect the high molecular weight protein-polymer conjugate peak, 289	
which no longer contained unreacted protein when analyzed by SEC (Figure 4A, red dashed curve) 290	
and SDS-PAGE (Figure 4B).  Because the molecular weight of the polymer is less than the 291	
molecular weight of the protein, we anticipate that most or all of the unreacted polymer was 292	
removed through SEC purification. However, because polymer alone does not stain on the protein 293	
gel, it is possible that some unreacted polymer remains following SEC purification.  294	
The purified protein-polymer conjugates contained a mixture of conjugates at 295	
protein:polymer ratios of 1:1 and 1:2 (Figure 4B).  On SEC, we did not observe any products of 296	
the conjugation reaction that would suggest more than one protein per conjugate, based on analysis 297	
of retention time of the protein-polymer conjugation reactions.  However, it is possible that any 298	
conjugates with two proteins joined by one or more polymers may elute at a longer retention time 299	
than would be predicted for a globular protein of the same molecular weight, so it remains possible 300	
that some protein-polymer conjugates containing two proteins exist in our reaction mixture. The 301	
lack of molecules in the conjugation reaction mixture eluting at less than 20 min retention time 302	
does conclusively indicate a lack of higher order aggregates. 303	
 304	
Figure 4.  Purification of hTF-PVDMA-mTEG conjugates. (A) SEC was used to analyze and purify hTF-PVDMA-305	
mTEG conjugates from unreacted hTF and from unreacted PVDMA-mTEG. Larger molecules have a shorter retention 306	
time.  Pure hTF protein (red solid line) exhibits a single narrow peak for absorbance at 220 nm.  The protein-polymer 307	
conjugation reaction (black dashed line) has overlapping peaks that include an unreacted hTF peak and a new larger 308	
molecule with shorter retention time consistent with protein-polymer conjugates, as well as a low molecular weight 309	
peak from polymer byproducts.  There are no peaks in the conjugation reaction that elute < 20 min, indicating the 310	
absence of higher order protein-polymer aggregates.  Following collection of the protein-polymer conjugate peak and 311	
reinjection onto SEC, a narrow peak is observed as purified hTF-PVDMA-mTEG (red dashed line). (B) SDS-PAGE 312	
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analysis of hTF (lane 1), protein-polymer conjugation reaction before purification (lane 2), and SEC purified hTF-313	
PVDMA-mTEG conjugate (lane 3) demonstrates successful purification of conjugates using SEC.  In the purified 314	
product (lane 3), unreacted hTF is absent. Polymers are at lower molecular weight than hTF and should therefore also 315	
be removed by SEC purification. Molecular weights of purified conjugates are consistent with protein:polymer ratios 316	
of 1:1 and 1:2.  Samples are not reduced.  317	
 318	
Fluorescent, Hydrophobic Small Molecule can be Coupled to PVDMA-mTEG Prior to Polymer 319	
Conjugation to Protein.  To permit visualization of protein-polymer conjugates in the presence of 320	
cells using fluorescence imaging techniques, we fluorescently labeled PVDMA-mTEG with the 321	
amine-functionalized fluorophore fluorescein cadaverine (FC, labeled polymer denoted as 322	
PVDMAFC-mTEG). Coupling a small molecule fluorophore directly to the polymer models a way 323	
in which drugs could be tethered to the polymer for future drug delivery applications.  FC was 324	
reacted with PVDMA-mTEG in DMSO in a molar ratio of FC to VDMA monomer such that 1-2 325	
molecules of FC were coupled to each polymer chain. Many small molecule drugs are 326	
hydrophobic, and the ability to couple drugs to polymer in organic solvent prior to an aqueous 327	
reaction conjugating polymer to protein is an advantage of our approach. We then coupled the 328	
fluorescently labeled PVDMAFC-mTEG to hTF and to the protein ovotransferrin (OTF). OTF is the 329	
chicken homolog of human transferrin. It has the same overall structure and size as human hTF, 330	
but is sufficiently distinct in sequence that it does not bind to human TFR62, making OTF conjugates 331	
a suitable negative control for TFR binding and internalization experiments.  FC labeled protein-332	
polymer conjugates were purified from unreacted molecules by SEC as described above, yielding 333	
a single pure peak when analyzed by SEC (Figure 5A). The peak exhibits absorbance at 220 nm 334	
(Figure 5A, top) and at 494 nm (Figure 5A, bottom). Absorbance at 494 nm is characteristic of the 335	
fluorophore, and is absent in the sample of pure protein, indicating successful conjugation of FC 336	
to polymer, and subsequent conjugation of PVMDAFC-mTEG to protein.  Analysis of the purified 337	
FC labeled protein-polymer conjugates using UV-visible spectroscopy resulted in absorbance 338	
peaks at 280 nm and 494 nm (Figure 5B).  In pure hTF protein, there is only an absorbance peak 339	
at 280 nm.  In PVDMA-mTEG without FC conjugation, we see no absorbance peaks in the UV-340	
visible range, as expected (Figure S1B). The presence of the 494 nm absorbance peak in the FC-341	
coupled PVMDA-mTEG and in the purified protein-polymer conjugates confirms that FC was 342	
successfully conjugated to PVDMA-mTEG and that PVDMAFC-mTEG subsequently was able to 343	
be conjugated to hTF and OTF.  344	
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 345	
 346	
Figure 5.  Fluorescent, hydrophobic small molecule can be coupled to polymer and protein-polymer 347	
conjugates. Small molecule fluorophore fluoresceine cadaverine (FC) was conjugated to PVDMA-mTEG, and the 348	
resulting PVDMAFC-mTEG was conjugated to hTF or OTF. (A) SEC was used to purify and analyze hTF-PVDMAFC-349	
mTEG and OTF-PVDMAFC-mTEG conjugates from unreacted component molecules.  A single peak for hTF-350	
PVDMAFC and for OTF-PVDMAFC with retention time shorter than for the corresponding protein alone, and with 351	
absorbance at 220 nm (top) and for 494 nm (bottom), demonstrates small molecule fluorophore incorporation into 352	
the purified protein-polymer conjugates. Protein alone does not absorb at 494 nm.  The FC molecule absorbs at 494 353	
nm. (B) UV-Vis absorption spectra for hTF protein, PVDMAFC-mTEG, purified hTF-PVDMAFC-mTEG, and purified 354	
OTF-PVDMAFC-mTEG.  The characteristic absorption peaks for protein (*) and FC (**) are indicated at 280 nm and 355	
494 nm, respectively. Concentrations of samples differ, resulting in different heights of absorbance peaks. 356	
 357	
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Internalization of Protein-polymer Conjugates into Cells is Receptor-specific.  We next 358	
determined that protein-polymer conjugates are specifically internalized through receptor-359	
mediated endocytosis.  MCF-7 breast cancer cells have been shown to overexpress the transferrin 360	
receptor on their surface and have been previously used to study internalization of molecules 361	
targeted to TFR.63,64 Flow cytometry with an antibody that recognizes human TFR confirmed high 362	
levels of surface TFR expression on the MCF-7 cell line (Figure S2A). A titration binding assay 363	
was performed with fluorescently labeled hTF and MCF-7 cells to determine an appropriate 364	
concentration of protein or protein-polymer conjugate for cell internalization experiments. We 365	
determined a dissociation constant (KD) of 10 ± 5 nM (Figure S2B), which is consistent with 366	
previously reported values.56 A biological interpretation of the KD is that  half of the receptors are 367	
occupied by ligand when the ligand concentration is equal to the KD. In subsequent conjugate 368	
internalization experiments, we incubated MCF-7 cells with 10 nM of conjugates to provide ample 369	
ligand to visualize receptor-specific internalization, without overwhelming the receptor 370	
internalization machinery.   371	
All internalization experiments were conducted by incubating protein-polymer conjugate 372	
samples or control samples with MCF-7 cells for 1 h at 37 °C in culture media without serum.  373	
These conditions are on the time scale and at the relevant temperature for receptor-mediated 374	
endocytosis to occur in MCF-7 cells.65 Prior to imaging, all cells were stained with phalloidin 375	
(shown by red fluorescence), which binds to actin filaments and demarcates cell boundaries, and 376	
DAPI (shown by blue fluorescence), which stains cell nuclei. All protein, protein-polymer, and 377	
polymer samples were fluorescently labeled with either Alexa Fluor 488 (AF488, samples with 378	
protein only) or FC (all polymer-containing samples) and are shown as green fluorescence.  379	
Row 1 of Figure 6 shows confocal microscopy images for MCF-7 cells stained with DAPI 380	
and phalloidin to identify nuclei and actin filaments, but with no protein, polymer, or conjugates 381	
added; these images show the level of background cellular autofluorescence in the channel that 382	
was used to visualize targeting molecules. Row 2 of Figure 6 shows confocal microscopy images 383	
for MCF-7 cells incubated with 10 nM hTF-488. The green channel and merged images show 384	
punctate regions of green fluorescence distributed throughout the cell body (cell boundaries shown 385	
in red channel), indicating internalization of the protein. The presence of punctate structures is 386	
consistent with protein localized to endosomes after receptor-mediated endocytosis. When treated 387	
with increasing concentrations of hTF-488, MCF-7 cells show increased levels of internalization 388	
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(Figure S3), also consistent with receptor-mediated endocytosis. To further demonstrate that 389	
ligand-receptor interactions are necessary for internalization, we conducted a competition 390	
experiment in which cells were treated with hTF-488 (10 nM) and a 1000-fold excess of unlabeled 391	
hTF (10 µM) (Figure 6, row 3). As expected, when labeled protein was in competition with an 392	
excess of unlabeled protein, green fluorescence signal within the cell body was reduced to the level 393	
of background autofluorescence (Figure 6, row 3). The results of these control experiments 394	
demonstrate that hTF is internalized into our MCF-7 cells via a mechanism consistent with 395	
receptor-mediated endocytosis.  396	
 397	
 398	
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Figure 6. hTF-PVDMAFC-mTEG targeted protein-polymer conjugates are internalized into MCF-7 cells 399	
through receptor-specific interactions.  Cells not treated with protein or protein-polymer conjugate exhibit a low 400	
background level of autofluorescence in the green channel (row 1). As a positive control, holo-transferrin protein 401	
directly labeled with fluorophore (hTF-488) is internalized into MCF-7 cells that express transferrin receptor, as seen 402	
by green punctate structures throughout the cell body (row 2).  hTF-488 internalization can be blocked by competition 403	
with an excess of unlabeled hTF protein (row 3). Fluorescently labeled polymer conjugated to human holo-transferrin 404	
(hTF-PVDMAFC-mTEG) is similarly internalized into the cell line (row 4). Competition between hTF-PVDMAFC-405	
mTEG and excess unlabeled hTF blocks internalization and reduces signal to the level of autofluorescence (row 5), 406	
indicating that binding and internalization of the protein-polymer conjugate is mediated by specific interactions 407	
between hTF its receptor, TFR.  Cells were incubated with samples for 1 h at 37 °C to allow receptor-mediated 408	
internalization to occur.  Blue indicates DAPI stain for cell nuclei; red indicates phalloidin conjugated to Alexa Fluor 409	
594, which stains actin filaments and helps to identify cell boundaries; and green indicates the protein or protein-410	
polymer conjugate, with positive control protein labeled with Alexa Fluor 488 or polymer labeled with fluorescein 411	
cadaverine. Scale bar shown applies to all images. 412	
 413	
Confocal microscopy images of MCF-7 cells treated with hTF conjugated to PVDMAFC-414	
mTEG (Figure 6, row 4) exhibited punctate regions of green fluorescence throughout the cell body, 415	
similar to results observed with hTF-488.  These results demonstrate successful internalization of 416	
the conjugates. A competition experiment similar to that described above for hTF-488 was 417	
performed in which cells were treated with hTF-PVDMAFC-mTEG conjugate in the presence of 418	
1000-fold excess (10 µM) unlabeled hTF. The green channel and merged confocal microscopy 419	
images for this experiment (Figure 6, row 5) reveal the reduction of green signal to the level of 420	
autofluorescence, indicating that the internalization of hTF-targeted protein-polymer conjugates is 421	
dependent on specific binding of hTF to TFR. Internalization of hTF-488 and of hTF-PVDMAFC-422	
mTEG molecules was further demonstrated by collecting a series of images from neighboring 423	
confocal planes of clusters of cells, termed z-stacks, confirming that green fluorescence is present 424	
within cells, rather than on the cell surface (Supporting Information Video 1 and Video 2).    425	
We explored whether non-specific polymer interactions substantially contributed to the 426	
binding and internalization signal we observed for hTF-PVDMAFC-mTEG (Figure 7). We co-427	
incubated hTF-PVDMAFC-mTEG with an excess of unlabeled PVDMA-mTEG, and observed no 428	
noticeable reduction in signal, suggesting that non-specific interactions of the polymer with the 429	
cell surface are not necessary for binding and internalization (Figure 7, row 1).    To further confirm 430	
that specific ligand-receptor interactions are required for internalization, we examined potential 431	
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binding and internalization of the negative control protein-polymer conjugate, OTF-PVDMAFC-432	
mTEG, which was not expected to bind any MCF-7 cell surface receptors. OTF is a chicken 433	
transferrin, and MCF-7 cells express human TFR. We did not observe any MCF-7 cell binding or 434	
internalization of OTF protein directly labeled with AF488 (Figure 7, row 2).  Similarly, we also 435	
did not observe MCF-7 cell binding or internalization of the non-targeted OTF-PVDMAFC-mTEG 436	
(Figure 7, row 3). Finally, fluorescently labeled polymer not conjugated to any protein (PVDMAFC-437	
mTEG) does not adhere to or internalize into MCF-7 cells (Figure 7, row 4). These results provide 438	
further confirmation that hTF-PVDMAFC-mTEG conjugates are internalized via specific 439	
interactions of the hTF ligand with cell surface receptor TFR, rather than through non-specific 440	
interactions of polymer with the cells. 441	
 442	
 443	
Figure 7.  Polymer does not cause non-specific cell staining for protein-polymer conjugates.  Including excess 444	
unlabeled polymer during the internalization period of hTF-PVDMAFC-mTEG does not block receptor-specific 445	
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internalization of hTF-PVDMAFC-mTEG (row 1).  MCF-7 cells neither bind nor internalize non-targeted chicken 446	
ovotransferrin protein labeled directly with fluorophore (OTF-488) (row 2) or fluorescently labeled OTF-polymer 447	
conjugates (OTF-PVDMAFC-mTEG) (row 3).  Fluorescently labeled polymer not conjugated to protein (PVDMAFC-448	
mTEG) similarly does not stain cells (row 4).  Blue indicates DAPI stain for cell nuclei; red indicates phalloidin 449	
conjugated to Alexa Fluor 594, which stains actin filaments and helps to identify cell boundaries; and green indicates 450	
the protein or protein-polymer conjugate, with OTF control protein labeled with Alexa Fluor 488 and polymer labeled 451	
with fluorescein cadaverine.  Scale bar shown applies to all images. 452	
 453	
When conjugating polymers to proteins, there is the risk that the polymer will destabilize 454	
the protein structure, or that the polymer will sterically block the interaction of a protein ligand 455	
with its receptor, rendering the protein-polymer conjugate irrelevant for the intended application. 456	
Importantly, the protein-polymer conjugate internalization experiments we have conducted 457	
demonstrate that hTF protein maintains its ability to bind and be internalized by TFR when 458	
conjugated to PVDMA-mTEG, suggesting that hTF maintains its structure and function when 459	
conjugated to PVDMA-mTEG. 460	
  461	
CONCLUSION 462	
 463	
We have developed a new, modular strategy for conjugating diverse proteins to hydrophilic 464	
polymers using the reactive, azlactone-functionalized polymer PVDMA with the goal of 465	
developing conjugates for applications in targeted drug delivery. In our approach, we first 466	
functionalized PVDMA with mTEG to render the polymer water-soluble. We demonstrated the 467	
conjugation of this reactive polymer with proteins in aqueous solution. When the targeting protein 468	
holo-transferrin was conjugated to a fluorescently-labeled analog of PVDMA-mTEG, protein-469	
polymer conjugates were internalized into tumor cells expressing the transferrin receptor in a 470	
receptor-specific manner.  471	
Internalization of hTF-PVDMA-mTEG conjugates into human cells expressing TFR has 472	
implications for targeted delivery to the central nervous system and to tumor cells with 473	
overexpressed receptors.4,56,60,66–68 Our approach to synthesizing protein-polymer complexes for drug 474	
delivery could be extended to encompass protein ligands that bind other receptors relevant for a 475	
variety of clinical needs to generate protein-polymer-drug conjugates for diverse targeted drug 476	
delivery applications. Although in this initial report proteins were conjugated to PVDMA through 477	
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primary amines contained naturally in the native protein sequences, both the targeting protein and 478	
the polymer could be further modified for site-specific conjugation reactions. 479	
While the experiments described here focused on mTEG-modified PVDMA, this post-480	
polymerization modification approach to the synthesis of multifunctional bioconjugates permits 481	
rapid and straightforward access to a broad range of macromolecular structures without requiring 482	
the synthesis of new polymers each time a new structure is to be investigated. For example, diverse 483	
side chain chemistries and degrees of functionalization can readily be explored. In addition, 484	
because the polymer modification reactions are conducted initially in organic solvents, non-water 485	
soluble functionality, such as hydrophobic drugs, may be incorporated into the polymer prior to 486	
conjugation to the proteins. The synthetic versatility of PVDMA and the ease with which it can be 487	
conjugated to proteins offers opportunities for preparing a range of bioconjugates tailored to 488	
specific biomedical applications. 489	
 490	
EXPERIMENTAL PROCEDURES 491	
 492	
Materials. Triethylene glycol monomethyl ether (mTEG), 1,8-diazabicylo[5.4.0]undec-7-ene 493	
(DBU), 2,2’-azobis(2-methylpropionitrile) (AIBN), 2-(dodecylthiocarbonothioylthio)-2-494	
methylpropionic acid, ovotransferrin (OTF), 4-iodoanisole, and anhydrous dioxane were 495	
purchased from Sigma Aldrich and used without further purification unless otherwise noted. The 496	
monomer 2-vinyl-4,4-dimethylazlactone (VDMA) was synthesized as previously described.69 497	
Fluorescein cadaverine (FC) was purchased from Biotium. Alexa Fluor 488 tetrafluorophenyl 498	
ester, NuPAGE 4-12% Bis-Tris gels, MES buffer, and LDS buffer were purchased from 499	
ThermoFisher Scientific. Inhibitor removal resin was purchased from Alfa Aesar. Holo-transferrin 500	
(HTf, Cat.: 616397) was purchased from CalBiochem. PBS (10X) were purchased from Fisher 501	
Scientific. THF was purified using alumina drying columns. All other solvents were purchased 502	
from Pharmco-AAPER (Brookfield, CT). Deuterated DMSO (DMSO-d6) and deuterated 503	
chloroform (CDCl3) were purchased from Cambridge Isotope Laboratories, Inc. Dulbecco’s 504	
Modified Eagle’s Medium (DMEM) was purchased from ATCC, and all other cell culture reagents 505	
were obtained from Gibco. Phalloidin conjugated to Alexa Flour 594 was purchased from Thermo 506	
Fisher, formaldehyde as a 3.7% solution in PBS was from Fisher Scientific, and Vectashield 507	
mounting medium with DAPI was from Vector Labs. 508	
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 509	
General Considerations. 1H-NMR spectra were collected on a Bruker 500 MHz NMR 510	
spectrometer. Attenuated total reflectance infrared (ATR-IR) spectra were obtained using a Bruker 511	
ALPHA FTIR spectrometer and analyzed using OPUS software version 7.5. Gel-permeation 512	
chromatography (GPC) was performed on an Agilent 1260 GPC instrument equipped with PLgel 513	
Mixed C and Mixed D columns and an RI detector, operating in THF at 40 °C with a flow rate of 514	
1 mL/min. Molecular weights and dispersities were measured against polystyrene calibration 515	
standards. SEC was performed using a Superdex 75 10/300 GL column (GE) and an Agilent 1200 516	
series liquid chromatography system. Flow cytometry was performed on a Guava easyCyte flow 517	
cytometer (Millipore-Sigma). Laser scanning confocal microscopy images were acquired on a 518	
Leica TCS SP5 laser scanning confocal microscope and analyzed using LAS AF software version 519	
2.7.3.9723. 520	
 521	
Synthesis of poly(2-vinyl-4,4’-dimethylazlactone) (PVDMA). VDMA was passed through a 522	
phenolic inhibitor removal resin followed by passage through a short plug of silica gel prior to 523	
polymerization. The initiator 2,2ʹ-azobisisobutyronitrile (AIBN) was recrystallized twice from 524	
methanol prior to use. AIBN (5.9 mg, 0.036 mmol, 0.5 equiv.) and CTA (26 mg, 0.072 mmol, 1 525	
equiv.) was weighed into a 25 mL schlenk-flask equipped with a stir bar. Anhydrous toluene (4.5 526	
mL) was added to the flask and the mixture was stirred to dissolve the AIBN. VDMA (1.5 g, 10.8 527	
mmol, 150 equiv.) was added to the flask, the flask was capped with a septum and placed in a dry 528	
ice and isopropanol bath at ~7 torr. Atmosphere was purged from the flask using three freeze-529	
pump-thaw cycles and filled with nitrogen. The reaction solution was stirred at 70 °C for 12 h 530	
(~85% conversion). The slightly viscous reaction mixture was cooled to room temperature and 531	
acetone (~3 mL) was added to the flask. The polymer was precipitated twice into hexanes to yield 532	
a pale yellow solid (1.26 g, 92% yield). 1H-NMR (500 MHz, CDCl3): δ = 1.37 (br s, (-CH3)2), 1.62-533	
2.1 (br m, -CH2CH-), 2.69 (br s, -CH2CH-). FT-IR (ATR, cm-1): 2980-2900 (C-H), 1820 (lactone 534	
C=O), 1672 (C=N). GPC: Mn = 13.1 kg/mol; PDI = 1.35. 535	
 536	
Synthesis of PVDMA-mTEG. PVDMA (100 mg, 0.72 mmol with respect to the molecular weight 537	
of the repeat unit VDMA) and mTEG (35 mg, 0.216 mmol, 0.3 equiv.) were combined in a 5 mL 538	
round-bottomed flask and dissolved in anhydrous THF (3 mL). DBU (16.1 µL, 0.108 mmol, 0.15 539	
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equiv.) was added to catalyze the reaction. 4-Iodoanisole (50.5 mg, 0.216 mmol, 0.3 equiv) was 540	
added as an internal standard for determining degree of functionalization. The flask was capped 541	
with a rubber septum and purged with nitrogen for 15 minutes. The reaction was stirred at 40 °C 542	
for 10 h. Prior to purification, an aliquot (~0.2 mL) of the reaction mixture was removed for 1H 543	
NMR analysis to determine the degree of mTEG functionalization. The remaining polymer 544	
solution was purified by precipitation into diethyl ether (100 mL) followed by centrifugation 545	
(9,000xg at 4℃, 2 min) to yield a yellow product. 1H-NMR (300 MHz, CDCl3): δ = 1.37-1.50 (br 546	
m, (-CH3)2), 1.62-2.1 (br m, -CH2CH-), 2.5 (br s, -CH2CH-), 2.84 (br s, -CH2CH-), 3.38 (br s, CH3-547	
O-), 3.45-3.65 (br m, -CH2-O-), 4.22 (br s, -C(=O)O-CH2). FT-IR (ATR, cm-1): 2880-2900 (C-H), 548	
1820 (lactone C=O), 1735 (ester C=O), 1672 (C=N), 1650 (amide C=O), 1540 (amide II CN and 549	
NH). 550	
 551	
PVDMAFC-mTEG. PVDMA-mTEG (50 mg, 0.26 mmol relative to the repeat unit) was dissolved in 552	
anhydrous DMSO (1 mL) in a 1.5 mL microcentrifuge tube. Fluorescein cadaverine (FC) (0.95 553	
mg, 1.3 µmol) was dissolved in anhydrous DMSO (9.5 µL) and added to the polymer solution. 554	
The reaction was mixed by gentle rotation for 2 h at room temperature. The labeled polymer was 555	
used for protein conjugation or hydrolysis without additional purification. 556	
 557	
Hydrolyzed PVDMAFC-mTEG. Unreactive, hydrolyzed PVDMAFC-mTEG used for control 558	
experiments was synthesized by dissolving PVDMAFC-mTEG (100 mg) in DMSO (2 mL) in a 5 559	
mL round bottom flask. Water (95.7 mg, 5.32 mmol, 10 eq relative to the azlactone repeat unit) 560	
and DBU (202 mg, 1.33 mmol, 2.5 eq relative to the azlactone repeat unit) was added and the 561	
solution was allowed to react at 40 °C for 3 h. Complete hydrolysis was confirmed using ATR-562	
FTIR spectroscopy. Samples were then dialyzed against PBS for 24 h (MWCO = 3.5 kDa) to 563	
remove any small molecule impurities, including unreacted fluorophore, prior to incubation with 564	
cells. FT-IR (ATR, cm-1):  3500-2600 (O-H), 2880-2900 (C-H), 1725 (carboxylic acid C=O), 1650 565	
(amide C=O), 1540 (amide II CN and NH). 566	
 567	
PVDMA-mTEG Hydrolysis Study. PVDMA-mTEG (244 mg, 1.32 mmol relative to the repeat 568	
unit) was dissolved in anhydrous DMSO (4.9 mL). PBS (11 mL) was added to simulate the 569	
concentration of polymer used in a 1:50 molar ratio conjugation of hTF to polymer. At each time 570	
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point (0.5, 1, 3, 5, 9, 12, 24, 36 hours), a 1 mL sample (15.3 mg of polymer) was flash frozen in 571	
liquid nitrogen and freeze dried. The samples were dissolved in acetone and cast directly onto the 572	
ATR crystal for analysis by FT-IR spectroscopy. 573	
 574	
Synthesis of Protein-polymer Conjugates. Proteins (i.e., hTF and OTF) were conjugated to 575	
polymer using the following general procedure. Protein stock solutions of 1 mg/ml were prepared 576	
in PBS with 0.1 M sodium bicarbonate (pH = 8.0), to increase the reactivity of the primary amines 577	
of the protein. Polymer samples (i.e., PVDMA-mTEG or PVDMAFC-mTEG) (50 mg) were 578	
dissolved in DMSO (1 mL) in a microcentrifuge tube. A 1 ml aliquot of the desired protein (1 mg) 579	
was added to polymer solution to achieve a protein:polymer molar ratio of 1:50, where a mole of 580	
polymer was calculated using data from GPC analysis. The molecular weight of a monomer of 581	
VDMA is 139 g/mol.   Therefore, a molar ratio of 1 mol protein: 50 mol polymer is equivalent to 582	
a molar ratio of 1 mol protein: 241 mol VDMA monomer. For studies examining the effect on 583	
conjugation of the molar ratio of protein:polymer molecules, ratios of 1:5, 1:10, 1:20, and 1:50 584	
were compared. The samples were reacted at 4 oC with gentle rotation overnight. Samples were 585	
then dialyzed against PBS for 24 h (MWCO = 3.5 kDa) to remove any small molecule impurities, 586	
including unreacted fluorophore, if the sample was not being purified by SEC.   587	
  588	
Analysis of Protein-polymer Conjugates by SDS-PAGE. Sodium dodecyl sulfate-polyacrylamide 589	
gel electrophoresis (SDS-PAGE) was used to analyze conjugation of protein to polymers. 590	
NuPAGE LDS buffer (4X) was added to each sample to a final concentration of 1X, without 591	
reducing agent.  All proteins studied contain disulfide bonds, and therefore the absence of reducing 592	
agents can shift their apparent molecular weight from the predicted molecular weight. The samples 593	
were heated in a water bath for 10 min at 70 °C to denature the proteins. Samples were loaded onto 594	
a NuPAGE 4-12% Bis-Tris gel. The gel was run in NuPAGE MES running buffer (1X). Gels were 595	
then stained with Simply Blue Safe Stain. 596	
 597	
Protein-polymer Conjugate Purification.  Protein-polymer conjugation reactions were first 598	
concentrated and purified from low molecular weight species using a centrifugal filtration device 599	
with a MWCO of 10 kDa (EMD Millipore) and extensive washing with PBS.  The protein-polymer 600	
conjugation reaction was then purified by SEC on a Superdex 75 10/300 column (GE Healthcare 601	
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Life Sciences).  Fractions of interest were pooled and concentrated with a centrifugal filtration 602	
device with a 10 kDa MWCO. All samples were analyzed by SDS-PAGE and imaged on a BioRad 603	
ChemiDoc MP imaging system using Image Lab 6.0 software (BioRad).  604	
 605	
Cells, Cell Culture, and Receptor Detection.  The MCF-7 human breast cancer cell line (ATCC 606	
#HTB-22, acquired in 2018) was used to test internalization of protein-polymer conjugates via 607	
receptor-mediated endocytosis of TFR.  MCF-7 cells were cultured at 37 °C in a humidified 608	
atmosphere with 5% CO2 in DMEM with 10% fetal bovine serum, 100 U/ml penicillin, and 100 609	
µg/ml streptomycin. Cells were subcultured after reaching 80% confluency using 0.25% trypsin-610	
EDTA. The presence of human TFR on the surface of MCF-7 cells was confirmed with an anti-611	
human TFR antibody directly labeled with fluorescein isothiocyanate (antibody clone CY1G4, 612	
from BioLegend, Cat.: 334103).  MCF-7 cells were harvested with 0.05% trypsin-EDTA.  1 x 106 613	
cells were incubated with antibody at a 1:20 dilution in PBS with 0.1% bovine serum albumin 614	
(PBSA) for 30 min at room temperature with gentle rotation.  Cells were washed with PBSA to 615	
remove unbound antibody, resuspended in PBSA, and analyzed by flow cytometry. 616	
 617	
Internalization Assays and Confocal Microscopy.  MCF-7 cells were seeded in a 4-well Millipore 618	
EZ chamber slide using 4x104 cells/well and allowed to establish adherence and reach 50-80% 619	
confluency. The media was then replaced with serum-free DMEM containing the specified 620	
conjugate sample in a 500 µl total volume. hTF-488, hTF-PVDMAFC-mTEG, OTF-488, or OTF-621	
PVDMAFC-mTEG were added to the wells to a final concentration equivalent to 10 nM of protein 622	
per well.  For the internalization sample with hydrolyzed PVDMAFC that was not conjugated to 623	
protein, an amount of polymer equivalent to the amount of polymer in 10 nM of protein-polymer 624	
conjugate was used, as determined by measurement of samples by UV-vis spectroscopy, using 625	
absorbance at 494 nm due to the presence of fluorophore. For competition experiments with 626	
unlabeled hTF, 10 µM unlabeled hTF was included.  For the competition experiment with excess 627	
unlabeled polymer, 0.5 mg of hydrolyzed PVDMA-mTEG was included.  Samples were incubated 628	
for 1 h at 37 oC in a humidified environment with 5% CO2.  Media with samples were removed, 629	
and cells were washed with PBS. Cells were fixed with 3.7% formaldehyde for 5-10 minutes at 630	
room temperature, and washed with PBS. Cells were permeabilized by incubation with 0.1% 631	
Triton-X 100 in PBS at room temperature for 5 min, and washed with PBS. Actin filaments were 632	
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stained with an Alexa Fluor 594 conjugate of phalloidin to help identify cell boundaries by adding 633	
250 µl per well of phalloidin in PBS diluted following manufacturer’s protocol, and cells were 634	
washed with PBS. Wells were removed from the slide and Vectashield mounting media containing 635	
DAPI for staining cell nuclei was applied to the fixed samples.  Samples were then covered with 636	
1.5 mm glass coverslips and sealed with transparent nail polish. Samples were imaged using a 63X 637	
oil immersion objective. Images were collected using sequential scanning, and an overlay of the 638	
sequential images was used to analyze internalization, for single focal plane images and for z-639	
stacks collected as a series of neighboring focal planes. 640	
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	 S2	
EXPERIMENTAL PROCEDURES 34	
Labeling hTF and OTF with Alexa Fluor 488. Holo-transferrin (hTF) or ovotransferrin (OTF) 35	
were labeled with Alexa Fluor 488 (AF488) by primary amine chemistry.  A solution of protein 36	
(1-2 mg/ml) was made in phosphate buffered saline (PBS). Sodium bicarbonate (1M stock 37	
solution) was added to the protein to a final concentration of 0.1 M to change the pH of the solution 38	
to 8.0. The fluorescent dye AF488 5-tetrafluorophenyl ester was dissolved in anhydrous DMSO to 39	
a final concentration of 11.3 nM. Dye was added to protein solution, using an amount of dye 40	
calculated following manufacturer’s protocol to achieve a desired molar excess of dye. The sample 41	
was incubated with gentle rotation at room temperature for 1 h. The protein labeled with AF488 42	
was then purified from free dye and concentrated using an Amicon centrifugal filtration device 43	
with a molecular weight cutoff of 10 kDa by washing extensively with PBS until the flow through 44	
was colorless. Concentrations and degree of labeling were determined using UV-Vis spectroscopy, 45	
measuring dye absorption at 494 nm (e = 71,000 cm-1 M-1).   Labeled protein was stored at 4 oC. 46	
 47	
Titration Binding Assay of hTF-488 with MCF-7 Cells.  Titration binding assays were performed 48	
to experimentally determine the binding affinity (dissociation constant, KD) of hTF with MCF-7 49	
cells. MCF-7 cells were harvested with 0.05% trypsin-EDTA. Aliquots of 1x105 cells were 50	
incubated for 1 h at 4 oC with a range of concentrations of fluorescently labeled hTF (hTF-488, 51	
0.5-500 nM) in PBS with 0.1% BSA (PBSA) with gentle rotation. Following incubation to reach 52	
equilibrium binding, cells were washed in PBSA and resuspended in PBSA for analysis. Data was 53	
collected and analyzed using flow cytometry. Experimental triplicate data was collected to 54	
determine the binding affinity of hTF to its receptor. For each replicate, the data were fit to a 55	
sigmoidal binding curve using Kaleidagraph software (Synergy). The concentration of hTF-488 56	
	 S3	
that resulted in the half-maximal value of each best-fit line was determined as the KD.  The mean 57	
of the three individually fit dissociation constants was determined and reported with the standard 58	
deviation.    59	
	 S4	
Figure S1 60	
 61	
 62	
Figure S1. PVDMA-mTEG analysis by size exclusion chromatography and UV-Vis 63	
spectroscopy.  (A) PVDMA functionalized with 0.3 molar equivalents of mTEG was analyzed on 64	
a Superdex 75 30/100 SEC column run at 0.4 ml/min, and absorbance was detected at 220 nm and 65	
at 494 nm. For absorbance at 220 nm, the functionalized polymer sample contains a broad peak 66	
characteristic of polymers with a molecular weight distribution eluting between 20 and 30 minutes, 67	
and a second peak of low molecular weight byproducts eluting around 50 minutes.  There is no 68	
absorbance at 494 nm. (B) PVDMA-mTEG analyzed using UV-Vis spectroscopy has no 69	
absorbance in the 240-700 nm range, as expected for the polymer.  70	
	 S5	
Figure S2 71	
 72	
 73	
Figure S2. MCF-7 cells express TFR and bind hTF. (A) MCF-7 cells, which are a human breast 74	
cancer cell line, express high levels of transferrin receptor (TFR) on their surface, as detected by 75	
an anti-human TFR antibody directly conjugated to fluorescein and analyzed by flow cytometry.  76	
(B) The binding of hTF to TFR was measured as the dissociation constant (KD) using an 77	
equilibrium binding assay.  MCF-7 cells were incubated with a range of concentrations of hTF 78	
directly labeled with Alexa Fluor 488 (hTF-488).  The assay was performed in experimental 79	
triplicate. Data from each replicate were fit to a sigmoidal curve, and the KD value was calculated 80	
for each replicate.  The KD is reported as the mean +/- standard deviation.  A representative binding 81	
curve is shown.   82	
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Figure S3. hTF-488 internalization into MCF-7 cells is concentration dependent. MCF-7 86	
cells, which are a human breast cancer cell line, express high levels of transferrin receptor (TFR) 87	
on their surface. Fluorescently labeled holo-transferrin (hTF-488) is internalized into the cells after 88	
incubation for 1 h at 37 °C.  Increasing the concentration of hTF-488 from 10 nM to 100 nM to 89	
1000 nM (rows 1, 2, and 3) shows increasing internalization, as visualized by increasing green 90	
signal within the cell boundaries.  Blue indicates DAPI stain for cell nuclei; red indicates phalloidin 91	
conjugated to Alexa Fluor 594, which stains actin filaments and helps to identify cell boundaries; 92	
and green indicates the protein fluorophore conjugate labeled with Alexa Fluor 488. Scale bar 93	
shown applies to all images.  94	
	 S7	
Description of supporting information videos.  To confirm the internalization of hTF-488 and 95	
hTF-PVDMAFC-mTEG, a series of consecutive focal planes were collected with confocal 96	
microscopy, referred to as z-stack series, using a step size of 0.5 µM. The data are available as .avi 97	
video files in Supporting Information.  In the videos, we observe that at the surfaces of the cells, 98	
we predominantly see phalloidin staining of actin filaments, indicated in red.  For both the hTF-99	
488 positive control molecule (SI_Video_1_hTF-488) and the hTF-PVDMAFC-mTEG protein-100	
polymer conjugate (SI_Video_2_hTF-PVDMA-FC-mTEG), we see that the fluorophore, shown 101	
in green, is contained within the cell boundaries, rather than at the cell surface, confirming 102	
internalization of molecules.  Blue indicates cell nuclei, stained with DAPI. 103	
